soul trial oral semaglutide cardiovascular outcomes

soul trial oral semaglutide cardiovascular outcomes (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Oral Semaglutide Cuts Cardiovascular Risk

Name: soul trial oral semaglutide cardiovascular outcomes (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Oral Semaglutide Cuts Cardiovascular Risk
Brand: begonvillage.com
SKU: 88480151286
Price: 29.15 USD
Availability: InStock
Rating: 4.6471 (10 reviews)

SKU: 88480151286

4.6

EUR29.15 EUR74.15

Pay in 4 interest-free payments of $7.29 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Oct 2 - Oct 7

Description

Cancer Cell 40 , 850864 (2022)

After having identical breakfasts at 8:00 am, blood samples were collected from the participants at 9:00 am (T1) followed by oral intake of their CMA or placebo